The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTI.L Regulatory News (CTI)

  • There is currently no data for CTI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

19 May 2010 15:32

RNS Number : 2180M
Cathay International Holdings Ld
19 May 2010
 



 

19 May 2010

 

Cathay International Holdings Limited

Interim Management Statement

 

Cathay International Holdings Limited (the "Company") announces its Interim Management Statement for the period from 1 January 2010 to 14 May 2010:

 

Highlights of the period

 

·; On 21 January 2010, the Company announced, inter alia, the appointment of Mr. Lee Jin Yi as an executive director and Chief Executive Officer of the Company and the appointment of Mr Eric Siu as Finance Director of the Company.

 

·; On 12 February 2010, the Company announced further investments in Xian Haotian Bio-Engineering Technology Co. Limited ("Xian Haotian") and its subsidiaries and related companies (the "Xian Haotian Group").

 

·; On 1 April 2010, the Company announced the flotation of Lansen Pharmaceutical Holdings Company Limited ("Lansen"), a subsidiary of the Company, on the Hong Kong Stock Exchange, and the associated partial disposal of Lansen.

 

·; On 27 April 2010, the Company announced the preliminary annual results of the Group for the year ended 31 December 2009.

 

·; On 6 May 2010, the Company announced the successful closing of the placing and public offer of shares in Lansen.

 

Further investments in the Xian Haotian Group

 

On 12 February 2010, the Company announced further investments in the Xian Haotian Group, following which Xian Haotian is now an indirectly wholly owned subsidiary of the Company. The investment made in the Xian Haotian Group during the period was approximately US$13 million, which brings the total investment made to date to approximately US$33 million.

The Xian Haotian Group is one of the Company's major investments in the healthcare and pharmaceutical sector in China. Going forward, inositol will be the core product of the Xian Haotian Group, and the Company anticipates that the inositol business will become a major contributor to the growth in the Group's profits in 2011 and beyond. The inositol project is expected to commence production in the second half of 2010.

 

Flotation and Partial Disposal of Lansen

 

As announced on 6 May 2010, the public offer of shares in Lansen was approximately 852 times oversubscribed and the flotation offer price was set at HK$3.91 per share. The net proceeds of the flotation payable to Lansen, after deducting fees and expenses, were approximately HK$350.4 million (US$45.1 million). The net proceeds of the partial disposal received by the Company were approximately HK$114.9 million (US$14.8 million). Dealings in Lansen's shares on the Hong Kong Stock Exchange commenced on 7 May 2010.

 

Following completion of the flotation and the partial disposal, the Company indirectly holds approximately 52.46% of Lansen. Assuming that the over-allocation option provided under the terms of the flotation is exercised in full, the Company will indirectly hold approximately 50.56% of Lansen.

 

The effect of the flotation and partial disposal on the financial position of the Group has been an increase in net assets.

 

The financial performance of the Group in the period since the 2009 year end have been in line with the Company's expectations, and the outlook for the full year remains unchanged that expressed in our preliminary announcement of results on 27 April 2010.

 

Except for the further investment in the Xian Haotian Group and the net proceeds received from the flotation and partial disposal of Lansen, there has been no significant change to the financial position of the Group since that reported as at 31 December 2009.

 

 

For further information, please contact:

 

Eric Siu (Finance Director)

Patrick Sung (Director and Controller)

(via Brunswick)

020 7404 5959

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSZKLFFBEFLBBK
Date   Source Headline
29th Jan 20187:18 amRNSLansen Change of Director
27th Dec 201712:39 pmRNSUpdate on Settlement of A Litigation
22nd Sep 201711:05 amRNSResults of Special General Meeting
19th Sep 201710:15 amRNSLansen's second share reduction plan of Starry
1st Sep 20173:11 pmRNSUpdate on Litigation against Lansen's subsidiary
30th Aug 20179:48 amRNSInterim Results for Six Months Ended 30 June 2017
30th Aug 20179:45 amRNSNotice of Special General Meeting
16th Aug 20177:00 amRNSNotice of Results
21st Jun 201711:55 amRNSResult of AGM
20th Jun 20177:00 amRNSSettlement of insurance claims received by Lansen
19th Jun 201711:54 amRNSLansen's declaration & payment of special dividend
7th Jun 201710:14 amRNSLansen's proposal to approve a special dividend
28th Apr 20177:00 amRNSAnnual Report and Accounts
7th Apr 201711:37 amRNSHoldings in Company
31st Mar 20179:50 amRNSLansen subsidiary enters distribution agreement
30th Mar 20179:20 amRNSAnnual Results for the Year Ended 31 December 2016
16th Mar 20177:00 amRNSNotice of Annual Results 2016
15th Mar 201711:57 amRNSNotification of class 2 transaction
9th Mar 20179:05 amRNSLansen's share reduction plan of Starry
20th Sep 201610:44 amRNSEntrusted Manufacturing Framework Agreement
31st Aug 20169:48 amRNSHalf-year Report
17th Aug 20167:00 amRNSNotice of Interim Results 2016
13th Jul 201611:02 amRNSResult of Lansen EGM
24th Jun 20161:15 pmRNSLansen Shares Subscription and Agreement
20th Jun 201611:17 amRNSResult of AGM
5th May 20161:00 pmRNSNotification of Transactions
5th May 20161:00 pmRNSClarification Announcement - transaction in Shares
5th May 20161:00 pmRNSNotification of Transactions
22nd Apr 20168:10 amRNSAnnual Report and Accounts
5th Apr 201610:11 amRNSDirector Appointment
30th Mar 201610:01 amRNSAnnual Results for the Year Ended 31 December 2015
24th Mar 20169:21 amRNSNotification of class 2 transaction
16th Mar 201610:01 amRNSNotice of Annual Results 2015
9th Mar 201610:04 amRNSStarry IPO
7th Mar 201610:34 amRNSLansen's release of its Trading Update
17th Feb 20168:50 amRNSLansen's Starry, obtains listing approval
29th Dec 20158:45 amRNSTrading Update
1st Dec 20155:51 pmRNSHolding(s) in Company
28th Aug 201510:12 amRNSHalf Yearly Report
17th Aug 20157:00 amRNSNotice of Interim Results
6th Jul 201510:25 amRNSLitigation against Lansen's sub in Ningbo, the PRC
15th Jun 20151:18 pmRNSLansen enters a distribution agreement with Botai
11th Jun 20159:38 amRNSDistribution agreement with Bio-Rad China
5th Jun 20157:01 amRNSAppointment of New Chairman
5th Jun 20157:00 amRNSResult of AGM
11th May 20157:00 amRNSAppointment of Broker
17th Apr 20159:03 amRNSTransaction in Own Shares
16th Apr 20153:44 pmRNSAnnual Report and Accounts
15th Apr 20158:59 amRNSTransaction in Own Shares
9th Apr 20157:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.